



**J. AARON GRANTHAM, MD, JOINS CORINDUS VASCULAR ROBOTICS
AS CHIEF MEDICAL OFFICER**

*Dr. Grantham will lead initiatives to educate the interventional cardiology community on
benefits of robotic therapy*

WALTHAM, MA – August 3, 2016 – Corindus Vascular Robotics, Inc. [NYSE MKT: CVRS], a leading developer of precision vascular robotics, today announced that J. Aaron Grantham, MD, a leading interventional cardiologist, and an innovator in the treatment of chronic total occlusions (CTOs), has joined the company as Chief Medical Officer (CMO).

Dr. Grantham will be spearheading Corindus' initiatives to educate the interventional cardiology community on the benefits of robotic therapy and will be leading efforts to develop clinical data to advance the CorPath® System's applicability for additional clinical indications. As a practicing CMO, Dr. Grantham will continue treating patients at Saint Luke's Mid America Heart Institute.

"I am excited to be joining Corindus during this time of growth for the company," said Dr. Grantham. "I believe that through a systematic, program-based approach, similar to my work in building CTO programs, robotic therapy will be able to reach its full potential. I look forward to working with other leaders in the field of interventional cardiology as we continue to optimize robotic therapy."

Dr. Grantham is with Saint Luke's Mid America Heart Institute, a member of Saint Luke's Health System, as Associate Professor, University of Missouri-Kansas City School of Medicine. He also is Director of the school's Cardiovascular Disease Fellowship Program and Director of Cardiovascular Medical Education at Saint Luke's Hospital.

"Dr. Grantham's experience, knowledge and thought leadership will play an integral role in our continued growth and success," said Mark Toland, President and Chief Executive Officer of Corindus "Together with an esteemed steering committee, Dr. Grantham will help Corindus achieve our vision and build a strong clinical roadmap for CorPath. We are excited to welcome him to the company in this critical position."

About Corindus Vascular Robotics, Inc.

[Corindus Vascular Robotics, Inc.](http://www.corindus.com) is a global technology leader in robotic-assisted vascular interventions. The company's CorPath® System is the first FDA-cleared medical device to bring robotic precision to complex, radial, coronary and peripheral procedures. During the procedure, the interventional cardiologist sits at a radiation-shielded workstation to advance stents and guidewires with millimeter-by-millimeter precision. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries. With the CorPath System, Corindus Vascular Robotics brings robotic precision to complex, radial, coronary and peripheral procedures to help optimize clinical outcomes and minimize the costs associated with complications of improper stent placement with manual procedures. Corindus stands behind its product with its unique \$1,000 hospital credit "One Stent Program." For additional information, visit www.corindus.com, and follow @CorindusInc.

Forward Looking Statements

Statements made in this release that are not statements of historical or current facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Corindus to

be materially different from historical results or from any future results or projections expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward looking statements. In addition to statements that explicitly describe such risks and uncertainties, readers are urged to consider statements in the conditional or future tenses or that includes terms such as “believes,” “belief,” “expects,” “estimates,” “intends,” “anticipates” or “plans” to be uncertain and forward-looking. Forward-looking statements may include comments as to Corindus’ beliefs and expectations as to future events and trends affecting its business and are necessarily subject to uncertainties, many of which are outside Corindus’ control.

Examples of such statements include statements regarding:

- Dr. Grantham serving as a practicing CMO while spearheading Corindus initiatives to educate the interventional cardiology community on the benefits of robotic therapy,*
- Dr. Grantham leading efforts to develop clinical data for the CorPath System while advancing the product's roadmap and its applicability for additional clinical indications,*
- that this is a time of growth for the company and that robotic therapy will reach its full potential by building a systematic, program-based approach,*
- that Dr. Grantham will play an integral role in the company's continued growth and success and*
- that together with an esteemed steering committee, Dr. Grantham will help the company achieve its vision and build a strong clinical roadmap for CorPath.*

Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are described in the sections titled "Risk Factors" in the company's filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as reports on Form 8-K, including, but not limited to the following: the rate of adoption of our CorPath System and the rate of use of our cassettes; risks associated with market acceptance, including pricing and reimbursement; our ability to enforce our intellectual property rights; our need for additional funds to support our operations; our ability to manage expenses and cash flow; factors relating to engineering, regulatory, manufacturing, sales and customer service challenges; potential safety and regulatory issues that could slow or suspend our sales; and the effect of credit, financial and economic conditions on capital spending by our potential customers. Forward looking statements speak only as of the date they are made. Corindus undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise that occur after that date. More information is available on Corindus' website at <http://www.corindus.com>.

###

Media Contacts:

Corindus Vascular Robotics
Brett Prince, VP Marketing
(508) 653-3335 ext. 231
Brett.prince@corindus.com

Yuliya Kutuzava
(203) 504-8230 ext. 131
corindus@knbcomm.com

Investor Contact:

Lynn Pieper Lewis
415-937-5202
ir@corindus.com